



Lesa, Chiesi Total Care pharmacist

FILSUVEZ[®] (birch triterpenes) topical gel Starter Kit

Indication and Important Safety Information

Indication

FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.

Warnings & Precautions

Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.

Please see accompanying full Prescribing Information for FILSUVEZ topical gel.

Filsuvez[®]
(birch triterpenes) topical gel

Filsuvez® (birch triterpenes) topical gel: The first treatment for both dystrophic and junctional epidermolysis bullosa

What's inside



Getting a Patient Started on FILSUVEZ

- Patient enrollment form
- Rx form
- Tube calculation worksheet



FILSUVEZ Access and Support Services



FILSUVEZ Dosing and Administration Guide



Copay Support Information

Please refer to the full Terms and Conditions in the back pocket for additional eligibility requirements.



US Prescribing Information



Contact Information Card





Filsuvez[®]
(birch triterpenes) topical gel

Indication and Important Safety Information

Indication

FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.

Important Safety Information

Warnings & Precautions

Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.

Adverse Reactions

The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).

Patient Counseling Information

Please refer to Prescribing Information for administration instructions.

To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information for FILSUVEZ topical gel.

For more information, visit FILSUVEZ.com/HCP

Chiesi Total CareSM Program offered through PANTHERx Rare Pharmacy.

© 2024 CHIESI USA.

FILSUVEZ[®] is a registered trademark owned by the Chiesi Group.
Chiesi Total CareSM is a service mark of CHIESI FARMACEUTICI S.p.A.

PP-FZ-0026 V3.0 2024

